International Summit VI : Hypertrophic Cardiomyopathy – A Contemporary and Treatable Disease : Diagnosis, Heart Failure Management and Prevention of Sudden Death
Seaport Hotel BostonBoston, USA Visit the Venue to read more
HCM Summit VI offers attendees an opportunity to learn the clinical, morphologic, and genetic spectrum of hypertrophic cardiomyopathy (HCM) from a renowned international faculty. We will explore a detailed contemporary view of HCM in which improved diagnostic techniques and management strategies have reduced disease mortality and vastly improved thousands of patients’ lives.
Practicing cardiologists, internists, pediatricians, nurses and other healthcare professionals with an interest in HCM.
Residents, fellows, and medical students.
Clinicians and basic researchers directly involved with HCM
Learner Objectives / Outcomes
Choose contemporary management strategies for high-risk and other patient subgroups, including: surgical septal myectomy, alcohol septal ablation, and prevention of sudden death with implantable defibrillators.
Outline the causes of sudden death in competitive athletes and the profile of HCM in athlete populations.
Outline the pros and cons of different mas screening strategies for detecting HCM in general populations.
Interpret new advances in drug treatment, relief of LV outflow obstruction with novel operative or percutaneous techniques and the potential application of systems biology and personalized medicine to HCM.
Identify HCM’s clinical, morphologic, and genetic spectra.
Understand the natural history, clinical course, and overall disease burden of HCM.
Review contemporary management strategies including surgical septal myectomy, alcohol septal ablation, and sudden death prevention through implantable defibrillators.
Assess and determine appropriate advanced heart failure management and selection of patients for heart transplant.
Understand atrial fibrillation’s disease burden and contemporary management strategies.
Explore mechanisms responsible for adverse clinical events and natural history.
Learn the roles of advanced diagnostic modalities including magnetic resonance imaging (MRI) and novel echocardiographic techniques.
Understand the clinical significance and occurrence of left ventricular out ow obstruction (at rest and with provocation), and the natural history of patients without obstruction.
Learn competitive athlete sudden death causes and HCM profile in athlete populations.
Understand the pros and cons of mass screening strategies to detect HCM in general populations.
Discover key technologic developments in diagnosis, sudden death risk assessment, and myocardial fibrosis detection with contrast MRI.
Learn new advances in drug treatment, animal models, and LV out ow obstruction relief via novel operative or percutaneous techniques.
Explore the potential applications of systems biology, personalized medicine, and dedicated worldwide HCM Centers (including those in developing countries).
Registration confirmation, conference information, and survey will be sent via email. You will receive a reminder email including a map with directions one week prior to Summit VI. If you do not receive this confirmation, please contact us to verify your registration.
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Seaport Hotel Boston
1 Seaport Lane
Boston, Massachusetts, United States Of America
Contact No.: +1 617-636-7000
The Boston Scientific Corporation
Ambry Genetics - Cardiology
Blueprint Genetics, Inc.
Contact No.: +1 617-636-7000